Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
RTOG 0848: adjuvant CXRT after gemcitabine misses OS overall (HR 0.96) but improves OS/DFS in node-negative pts (interaction P=.0063).
Adjuvant chemoradiation added to gemcitabine did not improve OS in resected pancreatic cancer (HR 0.96, 90% CI 0.79-1.18), so no broad RT role. The actionable signal is node-negative pts, where CXRT improved OS and DFS on interaction (P=.0063/.014) — hypothesis-generating, subgroup HRs not in source. Hepatobiliary carried the day's only news.
read the full digest →Studies · 107
- NRG Oncology/RTOG 0848OS primary EP not met (HR 0.96, 90% CI 0.79-1.18) adding adjuvant CXRT to gemcitabine; node-negative subgroup OS benefit on interaction (P=.0063).
- TROG 08.03 RAVES QOL SubstudyAt 5yr, 16% vs 2% severe urinary leakage aRT vs no RT (p=0.01); sRT timing had no QOL effect.
- STAMPEDE (abiraterone ± enzalutamide, high-risk non-metastatic)MFS HR 0.53 (6yr 82% vs 69%) and OS HR 0.60 adding 2yr abiraterone to ADT in high-risk M0 prostate (85% also had RT).
- TREASUREmOS 6.7 vs 13.4mo (HR 1.55, ns) adding consolidative TRT to atezo maintenance; halted early for SAEs 61% vs 18%.
- EANO Consensus Statement on Radiation NecrosisDelphi consensus (20 experts): 53/57 statements reached ≥80% agreement; perfusion MRI + amino-acid PET to distinguish RN from recurrence, bevacizumab for steroid-refractory RN.
- HYDRANo PFS difference vs conventional RT for either MHFRT type, but dose-escalated MHFRT alone raised late G2+ GI + bowel-QoL decrement; isodose 60/20 clean.
- ASTRO 2024: SBRT for Unfavorable Intermediate-Risk Prostate CancerModern 5-fraction SBRT (1-2% bothersome toxicity vs 10-30% for 2D-era 45fx) is now NCCN-endorsed for UIR prostate; focal-boost de-escalation is next.
- SUPREMO10yr chest-wall recurrence 1.1% vs 2.5% (HR 0.45), no DFS/OS gain, but trial prohibited RNI so tests incomplete PMRT.
- ESTRO Oral Cavity CTV Delineation GuidelinesNew consensus recipe for post-op CTV: recreate pre-op GTV-P +10mm composited with surgical defect/flap +5mm; standardizes OCSCC delineation at EQD2 60 Gy.
- 10-yr SBRT for Prostate Cancer (Meier Nonrandomized Trial)10-yr OS 84%, RFS 90% (94% LR, 86% IR); late G3 GU/GI ≤1.5%, no G4-5; 40Gy/5fx SBRT, no ADT, 21 centers
- American Radium Society AUC: Intraprostatic Recurrence After RTPSMA PET + mpMRI plus mandatory pre-salvage biopsy, then reirradiation (≤6 fx) over ADT alone, for radiorecurrent intraprostatic disease.
- NRG-GU005DFS superiority not met (HR 1.38, futility crossed); SBRT improved 2y bowel QoL (35% vs 44% MCID decline, p=0.034) vs MH-IMRT.